Adopt a moratorium on heritable genome editing
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index; 6 of the 14 sources its claims cite were checked for support.
Overview
CoChat Summary
TL;DR
The authors call for a global moratorium on all clinical uses of human germline editing, not a permanent ban, to allow time for an international governance framework. They propose voluntary national commitments, an initial fixed period (five years suggested), and conditions for any future approval.
Key findings
- The authors call for a global moratorium on clinical germline editing — changing heritable DNA in sperm, eggs or embryos — while explicitly excluding research that does not involve transferring an embryo to a uterus and excluding somatic-cell editing.
- About 30 nations already have legislation directly or indirectly barring all clinical germline editing; after an initial fixed period, a nation could allow a specific application only after public notice (perhaps two years), international consultation, transparent evaluation, and determination of broad societal consensus.
- The paper cites He Jiankui’s CCR5 editing as illustrating risk: disrupting CCR5 may increase complications and death from West Nile virus and influenza, and genetic enhancement is described as unjustifiable at this time.
- It notes IVF with preimplantation genetic testing can avoid transmitting severe genetic disease; IVF transfer leads to successful pregnancy in roughly 30% of cases in women under 35 and less than 10% in women over 40, while rare couples with 100% affected embryos are presented as the strongest case for considering clinical germline editing.
Methods
- This is a Comment/policy proposal, not an empirical study; it reports no new data collection or statistical analysis.
- The call has 18 signatories from 7 countries, including scientists and ethicists, and draws on prior summit statements, national academy reports, and cited literature.
- The main analysis is normative: it lays out the need for a moratorium, a possible international framework, proposed commitments, and a rationale for voluntary national pledges.
Limitations
- The paper states that its pledge is voluntary rather than a formal treaty; that a moratorium is not without cost; that assessing broad societal consensus is challenging; and that various framework aspects would need to be fleshed out by groups with appropriate international standing.
- Evident from the text: as a Comment, it offers no empirical evaluation of whether the proposed moratorium would be effective and no implementation data; it is a normative governance proposal rather than a tested intervention.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 2 Not valid · 4 Not checked · 20 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“About 30 nations currently have legislation that directly or indirectly bars all clinical uses of germline editing 1 , and they might choose to continue the morato rium indefinitely or implement a permanent ban.”
What the sources say
- Partly supportedcites [1] Araki, M. & Ishii, T. Reprod. Biol. Endocrinol. 12, 108 (2014). sourceExperimental — accuracy not yet measured
The International regulatory landscape section reports that 29 of 39 surveyed countries banned human germline gene modification. Figure 3 distinguishes 25 bans based on legislation from four based on guidelines, so the claim that about 30 nations have legislation overstates the count. The section also says it is unclear whether corrective genome editing would be illegal in some of those countries, so it does not establish a bar on all clinical uses. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Modifying disease risk by replacing genetic variants with alternative ones is fraught with challenges, because variants that decrease the risk of some diseases often increase the risk of others.”
What the sources say
- Partly supportedcites [6] Costas, J. Am. J. Med. Genet. B Neuropsychiatr. Genet. 177, 274–283 (2018). sourceExperimental — accuracy not yet measured
Section 1 identifies the Thr allele as increasing schizophrenia risk, while Section 8 says the alternative Ala allele is associated with hypertension risk and describes the variant as a possible example of antagonistic pleiotropy. This supports a disease-risk trade-off for one variant, but the paper does not establish that such trade-offs occur often or discuss the practical challenges of replacing genetic variants. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Indeed, an effort by the United Nations Educational, Scientific and Cultural Organization (UNESCO) to create a legally binding convention to outlaw human cloning foundered. This was in part because of the difficulty of achieving agree ment about rules for reproductive cloning to create a child, versus therapeutic cloning to create biologically compatible tissue to treat an existing person 10 .”
What the sources say
- Partly supportedcites [10] Langlois, A. Palgrave Commun. 3, 17019 (2017). sourceExperimental — accuracy not yet measured
The UNESCO Bioethics Programme section says UNESCO could not reach consensus on whether a convention banning human reproductive cloning was desirable. The Conclusion links some resistance to concern that negotiations would revisit earlier UN disagreements; the section on current international regulation identifies the reproductive-versus-therapeutic cloning divide in those UN debates. The claim therefore captures a contributing concern, but blurs UNESCO’s proposed ban on reproductive cloning with a broader ban on human cloning and its decision about whether to pursue a convention with disagreement over the convention’s rules. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The extent to which PGT diminishes IVF efficiency as a function of the IVF protocol, age of the mother, number of eggs harvested, and pro portion of affected embryos has not been extensively investigated. (We know of only one study addressing a few of these questions in a single setting 8 .)”
What the sources say
- Supportedcites [8] Steffann, J., Jouannet, P., Bonnefont, J. P., Chneiweiss, H. & Frydman, N. Cell Stem Cell 22, 481–482 (2018). source
The Main Text (page unavailable) identifies results from one PGD centre in Paris over five years. It examines maternal age, the number of good-quality embryos available for biopsy, and genetic risk in relation to embryo transfer. This supports the citation’s role as an example of a single-setting study addressing a few of the questions; the broader assessment of how extensively the topic has been investigated is the citing authors’ own framing. (LLM, conf=0.88)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although techniques have improved in the past several years, germline editing is not yet safe or effective enough to justify any use in the clinic.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
7 more claims
Create a free account to see all 32 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These articles, widely cited, 31,32 have serious limitations.”
From Human Germline and Heritable Genome Editing: The Global Policy Landscape (2020) · cites this paper as [32]
Experimental — accuracy not yet measured
Citations
Cites
CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury
Joy, M. T., Ben Assayag, E., Shabashov-Stone, D., Liraz-Zaltsman, S., Mazzitelli, J., Arenas, M., Abduljawad, N., Kliper, E., Korczyn, A. D., Thareja, N. S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.044 · Cited by 389
Araki, M., & Ishii, T. (2014) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-12-108 · Cited by 150
A global observatory for gene editing
Jasanoff, S., & Hurlbut, J. B. (2018) · Nature · doi:10.1038/d41586-018-03270-w · Cited by 136
Human germline genome editing and broad societal consensus
Baylis, F. E. (2017) · Nature Human Behaviour · doi:10.1038/s41562-017-0103 · Cited by 62
Self-citationCostas, J. (2018) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32545 · Cited by 58
Rethink public engagement for gene editing
Burall, S. (2018) · Nature · doi:10.1038/d41586-018-03269-3 · Cited by 49
Could Failure in Preimplantation Genetic Diagnosis Justify Editing the Human Embryo Genome?
Steffann, J., Jouannet, P., Bonnefont, J.-P., Chneiweiss, H., & Frydman, N. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.01.004 · Cited by 47
Building Capacity for a Global Genome Editing Observatory: Institutional Design
Saha, K., Hurlbut, J. B., Jasanoff, S., et al. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.04.008 · Cited by 31
Self-citationBuilding Capacity for a Global Genome Editing Observatory: Conceptual Challenges
Hurlbut, J. B., Jasanoff, S., Saha, K., et al. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.04.009 · Cited by 31
Self-citationHuman genome editing: ask whether, not how
Hurlbut, J. B. (2019) · Nature · doi:10.1038/d41586-018-07881-1 · Cited by 30
Research works printed but not linked: 1
- National Academies of Sciences, Engineering, and Medicine. Human Genome Editing: Science, Ethics, and Governance (National Academies Press, 2017).
Cited by
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“Importantly, in vivo gene editing strategies should only target somatic cell populations and must always avoid collateral germline editing, as clinical human germline editing raises serious ethical concerns (Lander et al., 2019; Saha et al., 2021).”
BackgroundSelf-citationGenome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020) · Plant Biotechnology Journal · doi:10.1111/pbi.13383 · Cited by 233
“After the report of gene-edited babies, a moratorium was called to establish an international framework (Lander et al., 2019).”
BackgroundInfluentialIn vivo somatic cell base editing and prime editing
Newby, G. A., & Liu, D. R. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.002 · Cited by 199
Self-citationDevelopment of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 181
“Applications in germline cells and embryos, whose DNA will be passed to future generations, have considerable ethical ramifications, and a community of scientists has recently called for a moratorium on germline editing for the purposes of implantation (see below) (Lander et al., 2019).”
BackgroundInfluentialSelf-citationPublic Acceptability of Gene Therapy and Gene Editing for Human Use: A Systematic Review
Delhove, J. M. K. M., Osenk, I., Prichard, I. J., & Donnelley, M. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.197 · Cited by 165
“73 The expansion of gene therapies into the medical arena, coupled with increased media exposure, is likely to change current perceptions.”
Metadata
- Authors
- Lander, E. S., Baylis, F., Zhang, F., Charpentier, E., Berg, P., Bourgain, C., Friedrich, B., Joung, J. K., Li, J., Liu, D., Naldini, L., Nie, J.-B., Qiu, R., Schoene-Seifert, B., Shao, F., Terry, S., Wei, W., & Winnacker, E.-L.
- Affiliations
- Broad Institute (US)
- Dalhousie University (CA)
- Max Planck Unit for the Science of Pathogens (DE)
- Stanford University (US)
- Université Paris Cité (FR)
- Humboldt-Universität zu Berlin (DE)
- Harvard University (US)
- Center for Excellence in Molecular Cell Science (CN)
- Vita-Salute San Raffaele University (IT)
- University of Otago (NZ)
- National Institute of Biological Sciences, Beijing (CN)
- Genetic Alliance (US)
- Peking University (CN)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Lander, Eric S.
- Baylis, Françoise
- Zhang, Feng
- Charpentier, Emmanuelle
- Berg, Paul
- Bourgain, Catherine
- Friedrich, Bärbel
- Joung, J. Keith
- Li, Jinsong
- Liu, David
- Naldini, Luigi
- Nie, Jing-Bao
- Shao, Feng
- Terry, Sharon
- Wei, Wensheng
- Winnacker, Ernst-Ludwig
- ORCID
- Venue
- Nature
- Published
- 2019-03-13
- Volume
- 567
- Issue
- 7747
- Pages
- 165-168
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2921153415
- Cited by
- 512
- References
- 11
- Citations by year
- 2026: 27 · 2025: 33 · 2024: 60 · 2023: 39 · 2022: 73 · 2021: 83 · 2020: 116 · 2019: 81
- FWCI
- 29.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Keywords
- germline editing, gene drive, moratorium, international governance, bioethics, germline modification, CRISPR/Cas9
- MeSH terms
- Gene Editing, Embryo, Mammalian, Female, Fertilization in Vitro, Gene Pool, Humans, International Cooperation, Male, Morals, Ovum, Social Change, Spermatozoa, Germ-Line Mutation, Risk Assessment, Genetic Predisposition to Disease, Heredity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adopt a moratorium on heritable genome editing. https://app.cochat.ai/papers/10.1038/d41586-019-00726-5
- The paper
- Lander, E. S., Baylis, F., Zhang, F., Charpentier, E., Berg, P., Bourgain, C., Friedrich, B., Joung, J. K., Li, J., Liu, D., Naldini, L., Nie, J.-B., Qiu, R., Schoene-Seifert, B., Shao, F., Terry, S., Wei, W., & Winnacker, E.-L. (2019). Adopt a moratorium on heritable genome editing. Nature. https://doi.org/10.1038/d41586-019-00726-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.